Sacituzumab Tirumotecan Improves PFS in Advanced NSCLC
Episode Summary
A phase 3 trial found sacituzumab tirumotecan plus pembrolizumab improved progression-free outcomes in first-line PD-L1-positive advanced NSCLC, while survival and safety data remain immature.